In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Calando Pharmaceuticals Inc.

Division of Arrowhead Pharmaceuticals Inc.
www.calandopharma.com

Latest From Calando Pharmaceuticals Inc.

Celgene’s Bet On Abraxis Helps Spur Host Of Nanomedicine Start-Ups

Second-generation therapeutics are moving into the clinic following Celgene’s successful gamble on Abraxane. New nanobiotechs proliferate, but an industry burned by other promising technology revolutions remains somewhat wary of investing in early-stage firms.

BioPharmaceutical Europe

Nanomedicine: Will It Get Big?

Big drugmakers will be watching closely to see if second-generation nanomed companies can program small particles to pack big pharmaceutical effects. We profile four start-ups that hope to show that they can: Blend Biosciences, Kala Pharma, Qualiber Technologies, and Uroboros Technologies.

BioPharmaceutical Europe

Restructuring for Success: Shifting Biotech Strategies

During a panel discussion at Elsevier Business Intelligence’s Therapeutic Area Partnerships conference in Boston in December 2011, experienced investors and biotech executives drew lessons from difficult restructurings and successful transitions.

BioPharmaceutical Business Strategies

Cerulean raises $15m series D to fund PhII cancer study

Cerulean Pharma, a leader in designing and developing nanopharmaceuticals, has closed a $15 million series D financing with participation from new investor CVF, as well as full participation from existing investors, including Polaris Venture Partners, Venrock, Lilly Ventures, Lux Capital, and Bessemer Venture Partners.

Cancer
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Arrowhead Pharmaceuticals Inc.
  • Senior Management
  • Larry G Stambaugh, Pres. & CEO
    Jeremy Heidel, CSO & VP, R&D
  • Contact Info
  • Calando Pharmaceuticals Inc.
    Phone: (626) 683-7200
    129 N. Hill Ave.
    Ste. 104
    Pasadena, CA 91106
    USA
UsernamePublicRestriction

Register